Nasdaq · CIK 0001385818
AYTU AYTU BIOPHARMA, INC
Insider trading from SEC Form 4. Last filing Jul 30, 2026. Close $2.03 on Oct 9, 2026, +5% from the 52-week low and -30% from the high.
In brief
AYTU BIOPHARMA, INC (AYTU) has 32 SEC Form 4 filings on file from 9 insiders, the latest filed on Jul 30, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
3 open-market trades have been scored at AYTU. The newest: Joshua R. Disbrow (Chief Executive Officer) bought $100k of stock on Jun 9, 2025, filed Jun 10, 2025, scored 57 (moderate). 2 insiders bought within 14 days of each other around Jun 9, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at AYTU BIOPHARMA, INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 57Moderate | Joshua R. Disbrow Chief Executive Officer buy | $100k 66,666 shares | +77% | +111% from low-26% from high | |
| 37Weak | Jarrett Disbrow Chief Business Officer buy | $25k 16,666 shares | +130% | +111% from low-26% from high | |
| 31Weak | Joshua R. Disbrow Chief Executive Officer buy | $20k 15,000 shares | +21% | - |
Transactions
Every row filed, 38 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 28, 2026 | Carl Dockery director | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 31,152 | Jul 30, 2026 |
| Jul 28, 2026 | John Donofrio Jr. director | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 23,762 | Jul 30, 2026 |
| Jul 28, 2026 | Joshua R. Disbrow Chief Executive Officer | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 237,203 | Jul 30, 2026 |
| Jul 28, 2026 | Greg Pyszczymuka Chief Commercial Officer | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 56,102 | Jul 30, 2026 |
| Jul 28, 2026 | Jarrett Disbrow Chief Business Officer | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 76,568 | Jul 30, 2026 |
| Jul 28, 2026 | Ryan J Selhorn Chief Financial Officer | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 74,743 | Jul 30, 2026 |
| Jul 28, 2026 | Vivian H Liu director | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 29,825 | Jul 30, 2026 |
| Jul 28, 2026 | Abhinav Jain director | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 29,500 | Jul 30, 2026 |
| Oct 3, 2025 | John Donofrio Jr. director | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 13,762 | Oct 7, 2025 |
| Oct 3, 2025 | Carl Dockery director | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 20,440 | Oct 7, 2025 |
| Oct 3, 2025 | Abhinav Jain director | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 19,500 | Oct 7, 2025 |
| Oct 3, 2025 | Vivian H Liu director | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 19,825 | Oct 7, 2025 |
| Oct 3, 2025 | Joshua R. Disbrow Chief Executive Officer | AGrant or award Common Stock | +31,446 | $0.00 | $0 | 184,703 | Oct 7, 2025 |
| Oct 3, 2025 | Ryan J Selhorn Chief Financial Officer | AGrant or award Common Stock | +16,243 | $0.00 | $0 | 32,243 | Oct 7, 2025 |
| Oct 3, 2025 | Jarrett Disbrow Chief Business Officer | AGrant or award Common Stock | +19,606 | $0.00 | $0 | 49,068 | Oct 7, 2025 |
| Oct 3, 2025 | Greg Pyszczymuka Chief Commercial Officer | AGrant or award Common Stock | +12,500 | $0.00 | $0 | 36,102 | Oct 7, 2025 |
| Oct 3, 2025 | Joshua R. Disbrow Chief Executive Officer | AGrant or award Common Stock | +22,500 | $0.00 | $0 | 207,203 | Oct 7, 2025 |
| Oct 3, 2025 | Ryan J Selhorn Chief Financial Officer | AGrant or award Common Stock | +17,500 | $0.00 | $0 | 49,743 | Oct 7, 2025 |
| Oct 3, 2025 | Jarrett Disbrow Chief Business Officer | AGrant or award Common Stock | +12,500 | $0.00 | $0 | 61,568 | Oct 7, 2025 |
| Jun 9, 2025 | Joshua R. Disbrow Chief Executive Officer | POpen-market purchase Common Stock | +66,666 | $1.50 | $100k | 153,257 | Jun 10, 2025 |
| Jun 9, 2025 | Jarrett Disbrow Chief Business Officer | POpen-market purchase Common Stock | +16,666 | $1.50 | $25k | 29,462 | Jun 10, 2025 |
| Jun 6, 2025 | Nantahala Capital Management, LLC owner | POpen-market purchase Prefunded Warrantsderivativeindirect: See footnote | +4,000,000 | $1.50 | $6.0M | 4,815,217 | Jun 9, 2025 |
| Mar 31, 2025 | Greg Pyszczymuka Chief Commercial Officer | MOption exercise Common Shares | +209 | - | - | 23,602 | Mar 31, 2025 |
| Mar 31, 2025 | Greg Pyszczymuka Chief Commercial Officer | MOption exercise Restricted Stock Unitsderivative | -209 | $0.00 | $0 | 0 | Mar 31, 2025 |
| Feb 28, 2025 | Joshua R. Disbrow Chief Executive Officer | POpen-market purchase Common Stock | +15,000 | $1.30 | $20k | 86,591 | Mar 3, 2025 |
| Feb 5, 2025 | Ryan J Selhorn Chief Financial Officer | MOption exercise Common Shares | +105 | - | - | 16,000 | Mar 3, 2025 |
| Feb 5, 2025 | Ryan J Selhorn Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -105 | $0.00 | $0 | 0 | Mar 3, 2025 |
| Dec 31, 2024 | Greg Pyszczymuka Chief Commercial Officer | MOption exercise Common Shares | +208 | - | - | 23,393 | Jan 2, 2025 |
| Dec 31, 2024 | Greg Pyszczymuka Chief Commercial Officer | MOption exercise Restricted Stock Unitsderivative | -208 | $0.00 | $0 | 209 | Jan 2, 2025 |
| Nov 11, 2024 | Ryan J Selhorn Chief Financial Officer | AGrant or award Common Shares | +14,000 | $0.00 | $0 | 15,895 | Nov 13, 2024 |
| Nov 6, 2024 | Greg Pyszczymuka Chief Commercial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +7,000 | $0.00 | $0 | 7,000 | Nov 8, 2024 |
| Nov 6, 2024 | Vivian H Liu director | AGrant or award Common Shares | +1,500 | $0.00 | $0 | 9,825 | Nov 8, 2024 |
| Nov 6, 2024 | Jarrett Disbrow Chief Business Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +7,000 | $0.00 | $0 | 7,000 | Nov 8, 2024 |
| Nov 6, 2024 | Joshua R. Disbrow Chief Executive Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +38,000 | $0.00 | $0 | 38,000 | Nov 8, 2024 |
| Nov 6, 2024 | Abhinav Jain director | AGrant or award Common Shares | +1,500 | $0.00 | $0 | 9,500 | Nov 8, 2024 |
| Nov 6, 2024 | John Donofrio Jr. director | AGrant or award Common Shares | +1,500 | $0.00 | $0 | 3,762 | Nov 8, 2024 |
| Nov 6, 2024 | Carl Dockery director | AGrant or award Common Shares | +1,500 | $0.00 | $0 | 10,440 | Nov 8, 2024 |
| Aug 11, 2023 | Vivian H Liu director | AGrant or award Common Shares | +1,500 | $0.00 | $0 | 8,325 | Nov 8, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Carl Dockerydirector
- Jarrett DisbrowChief Business Officer
- Joshua R. DisbrowChief Executive Officer
- John Donofrio Jr.director
- Abhinav Jaindirector
- Vivian H Liudirector
- Nantahala Capital Management, LLCowner, other
- Greg PyszczymukaChief Commercial Officer
- Ryan J SelhornChief Financial Officer
Questions about AYTU
Answered from the filings on this page, as of the latest one.
Are insiders buying AYTU?
No. In the last 90 days no insider at AYTU BIOPHARMA, INC bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade AYTU on the open market?
Joshua R. Disbrow (Chief Executive Officer) bought $100k of AYTU on Jun 9, 2025 and filed the Form 4 on Jun 10, 2025. InsiderTell scored 57 (moderate), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at AYTU BIOPHARMA, INC?
9 people have filed a Form 4 at AYTU BIOPHARMA, INC, among them Carl Dockery (director), Jarrett Disbrow (Chief Business Officer), Joshua R. Disbrow (Chief Executive Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.